ReviewHistopathology2017
NUT midline carcinoma of the larynx: an international series and review of the literature.
Review in Histopathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Anti-angiogenic therapy as a beacon of hope in the battle against pulmonary NUT midline carcinoma.Frontiers of medicine · 2025Pooled it
- Pediatric NUT Carcinoma Is a Rare and Challenging Tumor: Single Center Experience of Five Children.The oncologist · 2019Trial
- Several Considerations on the Pathology, Treatment, and Prognosis of Laryngeal NUT Carcinoma.Oncology and therapy · 2026Article
- The impact of histopathology on prognosis of squamous cell carcinoma of the larynx: can we do better?Virchows Archiv : an international journal of pathology · 2025Review
- Transcriptomic profiling of a late recurrent nuclear protein in testis carcinoma of the lung 14 years after the initial operation: a case report.Translational lung cancer research · 2024Article
- Molecularly defined sinonasal malignancies: an overview with focus on the current WHO classification and recently described provisional entities.Virchows Archiv : an international journal of pathology · 2024Review
- Nuclear protein in testis carcinoma of the lung.Translational oncology · 2023Review
- Intra-, para-, and suprasellar nuclear protein of testis carcinoma with infiltration of cavernous sinus and clivus-a case report.Acta neurochirurgica · 2022Article
- Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Hypopharynx, Larynx, Trachea and Parapharyngeal Space.Head and neck pathology · 2022Review
- NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report.Diagnostic pathology · 2022Article
- NUT Midline Carcinoma: A Rare Solid Tumour Characterized by Chromosome Rearrangement.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Malignant Sinonasal Tumors: Update on Histological and Clinical Management.Current oncology (Toronto, Ont.) · 2021Review
- Primary Thyroid NUT Carcinoma With High PD-L1 Expression and Novel MassiveFrontiers in oncology · 2021Article
- Case Report and Literature Review: Primary Pulmonary NUT-Midline Carcinoma.Frontiers in oncology · 2021Article
- YAP1-NUTM1 Gene Fusion in Porocarcinoma of the External Auditory Canal.Head and neck pathology · 2020Article
- Successful treatment of a case with NUT midline carcinoma in the larynx and review of the literature.Clinical case reports · 2020Article
- Clinicopathological Analysis of Five Cases of NUT Midline Carcinoma, including One with the Gingiva.BioMed research international · 2020Article
- Role of ancillary techniques in profiling unclassified laryngeal malignancies.Virchows Archiv : an international journal of pathology · 2018Review
- Maxillary Sinus NUT Carcinoma: A Case Report.Cancer diagnosis & prognosisArticle
- Supraglottic NUT Carcinoma: A Case Report and Literature Review.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 13 institutions in 7 countries.
Funding
Abstract
aimsNUT midline carcinoma (NMC) is a rare undifferentiated and aggressive carcinoma that locates characteristically to the midline of the head and neck, and mediastinum. NMC is characterized by chromosomal rearrangements of the gene NUT, at 15q14. The BRD4 gene on 19q13 is the most common translocation partner forming a fusion oncogene, BRD4-NUT. By the end of 2014, the International NUT Midline Carcinoma Registry had 48 patients treated for NMC. Laryngeal NMC are exceedingly rare, and we report a case series of seven cases. METHODS AND
resultsWe searched for cases in files of different hospitals as well as a thorough search of the English language literature. The diagnosis of NMC is made by demonstration of NUT rearrangement either by immunohistochemistry, fluorescence in-situ hybridization (FISH) or reverse transcription-polymerase chain reaction (RT-PCR). We found three previously published cases, and in this series add four cases of our own.
conclusionsNMC consists of monomorphic, often discohesive, cells with an epithelioid appearance and distinct nucleoli. The tumours typically show abrupt squamous differentiation. The mean age of the patients was 34 years, hence significantly lower than that for conventional laryngeal carcinoma. All tumours were located in the supraglottis and five patients died of the disease after 3, 7, 8, 9 and 11 months. Laryngeal NMC may be underdiagnosed, and an increased awareness among pathologists is warranted. NMC has characteristic morphological features, and positive immunostaining with the NUT antibody is diagnostic. Its aggressive behaviour demands a very intense treatment strategy and the need for its recognition is emphasized further by new promising treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.